Blood Transfusion Diagnostics Market Size Worth $5.8 Billion By 2027

The global blood transfusion diagnostics market size is expected to reach a value of USD 5.8 billion by 2027 registering a CAGR of 6.6%, according to a new report by Grand View Research, Inc. Growing prevalence of chronic diseases, such as anemia, sickle cell disease, hemophilia, cancer, and kidney disease, is significantly driving the market growth. According to the Sickle Cell Disease Coalition statistics, globally, the number of sickle cell disease cases is projected to increase by around 30% by 2050.According to NCBI statistics, liver diseases accounts for around 2 million deaths each year globally. Blood transfusion is crucial for patients with such chronic diseases, as it allows to exchange the diseased cells with the healthy RBCs without disrupting the blood viscosity.

Female transfused holding a tablet computer in hospital ward

According to the National Blood Transfusion Service (NBTS) database, a total of 60,236 donor screening was done between 2010 and 2016 at the National Blood Transfusion Center (NBTC), Eritrea. Among them, at least 3.6% of the donated blood showed positive results for TTI and 0.1% showed positive results for multiple infections. Some of the chronic infectious diseases, such as hepatitis B, hepatitis C, HIV, and syphilis, create the need for accurate donor screening, thus further driving the market growth of diagnostics. Transfusion is commonly used in cases of trauma, road accidents, surgeries, childbirth, and gastrointestinal bleeding to replace major blood losses.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/blood-transfusion-diagnostics-market

Further key findings from the report suggest:

Reagents and kits is expected to be the largest as well as the fastest-growing product segment from 2020 to 2027
The disease screening segment is projected to register the fastest CAGR over the forecast period
According to the WHO, screening of donated blood for detecting transfusion transmissible infections, such as hepatitis B & C and HIV, should be mandatory
The hospitals end-use segment is estimated to account for the second largest market share by 2027 on account of rising instances of Pretransfusion therapies being performed in hospitals as the therapy requires cross-matching tests between the donor and recipient
Asia Pacific is projected to be the fastest-growing regional market due to rising geriatric population, especially in China and Japan

Laboratory Proficiency Testing Market Size Worth $1.9 Billion By 2027

The global laboratory proficiency testing market size is expected to reach USD 1.9 billion by 2027, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 7.3% from 2020 to 2027. The market is driven by the increasing focus on water tests, legalization of medical cannabis, a growing number of cannabis testing laboratories, and increasing outbreaks of foodborne illnesses.

Government initiatives to carry out accurate and reliable proficiency testing are expected to drive the market. For instance, in October 2020, the Central Testing Laboratory of the Abu Dhabi Quality & Conformity Council implemented a PT program in collaboration with Biogenix Lab to verify the competency of medical laboratories carrying out COVID-19 tests.

Initiatives undertaken by the governments to raise awareness are anticipated to further boost market growth. For instance, in November 2020, the National Accreditation Board for Testing and Calibration Laboratories’ (NABL-IGS) awareness program was conducted to raise awareness about the significance of accrediting geotechnical laboratories in Kerala, India.

The increasing adoption of fully-automated instruments and automation in laboratories is expected to boost market growth. The presence of accreditation programs aimed to combat challenges, such as safety and complexity in the food supply chain, is expected to boost market growth. For instance, in March 2020, AOAC INTERNATIONAL expanded its Laboratory PT Program by adding testing for infant formula and adult nutritional and pH to ensure safety in the food supply chain.

The presence of new environmental protection regulations due to COVID-19 is expected to boost market growth. For instance, in June 2020, the Environmental Diagnostics Laboratory (EDLab) at Pure Air Control Services was accredited by the A2LA for testing environmental SARS-CoV-2

The market is highly competitive as there are a large number of organizations providing various programs. Furthermore, the prices vary between the organizations based on programs and additional discounts. The companies are focusing on the use of automated instruments and new programs continue gaining profits in the market. These new programs, coupled with the growing demand for safety and efficacy of food products and diagnostics owing to the SARS-CoV-2 pandemic, are expected to intensify competition over the coming years.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/laboratory-proficiency-testing-market

Further key findings from the report suggest:

The legalization of cannabis products in the U.S. in December 2018 and the gradual expansion of this market are propelling the need for the testing of safety and efficacy for medical use
The presence of food contaminants can cause more than 200 diseases, including diarrhea and cancer. Diarrhea affects nearly 550 million people and causes 230,000 deaths every year. Children aged below 5 years carry 40% of foodborne diseases, causing 125,000 deaths every year
In the U.K., over 130 million hematology tests are carried out each year
Calibration proficiency testing is another service being focused on, which is attributed to the growing scope of automation in laboratories
Organizations such as the American Proficiency Institute, LGC Ltd., and the College of American Pathologists developed several programs for laboratories to improve their quality and assess performance in testing COVID-19

Women’s Health Diagnostics Market Size Worth $30.8 Billion By 2025

The global women’s health diagnostics market size is expected to reach USD 30.8 billion by 2025, according to a new report by Grand View Research, Inc. Rising adoption of point-of-care diagnostics and growing incidence of various chronic and lifestyle diseases are among the key factors stimulating the growth of the market. Besides this, introducing various awareness programs is also anticipated to work in favor the market during the forecast period. For instance, in 2014, the European Commission launched joint action for European Guide on Quality Improvement in Comprehensive Cancer Control.

Women’s health diagnostics is witnessing high growth due to increased funding from various organizations. For instance, in May 2015, Abcodia received funding of USD 8.0 million from Cambridge Innovative Capital, Scottish Equity Partners, Albion Ventures, and UCLB to launch Risk of Ovarian Cancer Algorithm (ROCA) test in the U.K. for early detection of ovarian cancer.

On the basis of end use, the market has been bifurcated into hospital & diagnostics centers and home. Hospitals and diagnostic centers accounted for a larger share in the market due to high number of visits to hospitals and more reliable detection.

The market in Asia Pacific is likely to witness significant growth over the coming years. The growth of the market can be attributed to increasing investments in healthcare, growing focus of international device manufacturers on strengthening their distribution networks within the region, and epidemiological shift from infectious diseases to chronic diseases within regional boundaries.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/womens-health-diagnostics-market

Further key findings from the report suggest:

Increasing investments by governments and private bodies and rising disposable income are providing a push to the market
Cancer accounted for the highest share in the market in 2017. The segment will register noteworthy growth during the forecast period owing to availability of early detection tests and government initiatives to tackle cancer
Prenatal testing is estimated to be the fastest growing segment during the same period owing to rising prevalence of prenatal diseases, increasing maternal age, surging healthcare expenditure, and development of advanced diagnostic tests
Geographically, North America was the leading revenue contributor to the women’s health diagnostics market in 2017. It is anticipated to maintain its dominance through 2025, thanks to widening base of diagnostic and imaging centers, mounting cases of cancer, growing awareness about fertility testing, and spiraling adoption of point-of-care testing devices
Some of the key players are Siemens Healthcare Private Limited; Hologic, Inc.;GE Healthcare; F. Hoffmann-La Roche Ltd.; bioMérieux SA; Koninklijke Philips N.V; Abbott; Becton, Dickinson and Company, Quest Diagnostics, Inc.; and PerkinElmer, Inc.

Tissue Diagnostics Market Worth $6.6 Billion By 2027

The global tissue diagnostics market size is anticipated to reach USD 6.6 billion by 2027, growing at a CAGR of 5.9% during the forecast period, according to a new report by Grand View Research, Inc. Accelerating demand for automated tissue diagnostic systems due to the lack of skilled pathologists has driven the market. The advent of advanced imaging techniques, such as autofluorescence, that minimize the need for invasive diagnostics further supplement market growth.

The digitalization of tissue diagnostic techniques has resulted in the improvement of workflows and better patient care. Ongoing strategic models taken-up by key companies to enhance the efficiency of diagnostics also drives the market. For instance, in December 2019, Philips collaborated with Paige to provide clinical-grade artificial intelligence-based solutions to pathology laboratories. This enhanced the speed and accuracy of cancer diagnostics in laboratories.

Tissue diagnostic techniques, such as immunohistochemistry (IHC) or in situ hybridization, are used in companion diagnostics (CDx) to determine the quantity of a target analyte present in the sample. Introduction of CDx tests, such as the launch of the VENTANA HER2 Dual ISH CDx

Click the link below:
https://www.grandviewresearch.com/industry-analysis/tissue-diagnostics-market

Further key findings from the report suggest:

IHC tests are highly adopted as these tests are specific and helpful in identifying the variations between different types of cancer, resulting in the largest revenue share
A rise in the investments for the development of advanced infrastructure to digitalize images is anticipated to drive the digital pathology segment with the fastest CAGR.
Moreover, an increase in the demand for automated modalities owing to a dearth of skilled pathologists further compliments this growth
A large number of breast cancer cases coupled with a rise in the application of digital image processing techniques on histopathological samples for breast cancer detection contributes to the largest share of breast cancer
Prostate cancer is anticipated to register lucrative growth owing to the extensive ongoing research pertaining to early diagnosis and prevention of this disease
Hospitals dominated the market in terms of revenue share due to the high adoption of tissue diagnostics solutions. These solutions provide accurate results in minimal time than conventional testing procedures
North America accounted for the largest revenue share owing to increasing collaborations between pharmaceutical and biotech firms to expand their product offerings
The requirement of better laboratory management systems, growing demand for novel patient care facilities, and favorable regulatory framework, boost the Asia Pacific market at a lucrative pace
Abbott, QIAGEN, Roche, Siemens, Danaher, Thermo Fisher, and Merck are some key participants operating in the tissue diagnostics market
Key vendors are engaged in novel product developments, partnership, and acquisition models to maintain their revenue share in the market.

Neurological Biomarkers Market Size Worth $16.5 Billion By 2026

The global neurological biomarkers market size is expected to reach USD 16.5 billion by 2026, according to a new report by Grand View Research, Inc. It is estimated to register a CAGR of 14.5% over the forecast period, driven by an increasing prevalence of neurological diseases and emergence of novel diagnostic products.

Neurological biomarkers can be used for diagnostics, drug discovery, or personalized medicines among other applications. These products may be employed in drug development to reduce attrition rates during clinical trials. Some neurological biomarkers can further be used to predict drug failures early in the development process by determining their pharmacological effect on patients, which helps the pharmaceutical company obviate additional costs associated with further clinical trials.

There remains a significant dearth for in-depth knowledge of the pathophysiologies of several neurological disorders, thus resonating with the unmet need for more research and increased funding for the same. Though technological advancements and rising consumer awareness are flag-bearers in this market growth, there remains considerable scope for advanced diagnostics – in terms of precision, specificity, and test time.

The diagnostic landscape in this market is gradually shifting towards genetic testing and counseling. Biomarker signatures are a rising trend in the diagnosis and treatment of neurological diseases. This has resulted in non-invasive testing, faster drug development, and early diagnosis of abnormalities/diseases. Furthermore, digital biomarkers provide various pharmaceutical companies with contextual and supplemental information to conclude clinical trial decisions. For instance, IXICO plc is collaborating with biopharmaceutical companies to validate clinically digital biomarkers and use them in clinical trials.

Proactive initiatives by public and private organizations to heighten consumer awareness is a key driver of the neurological biomarkers market. For instance, the National Alliance on Mental Illness (NAMI) one of the largest grassroot organizations in the U.S. is dedicated to educating, advocating, and supporting mental health patients about diagnosis and apt treatment for their conditions. Such drivers reflect a prosperous future in the global biomarkers market.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/neurological-biomarkers-market

Further key findings from the report suggest:

Most biomarkers evaluating neuronal damage cannot be clinically useful individually, and are generally used in panels
Most cerebrospinal fluid biomarkers used in medical practice are amyloid β and tau proteins
Nascent products allow a broader scope for characterization and selection of treatment strategies
Inconsistent regulatory trends remain a major constraint for the market
Asia Pacific is positioned to witness the fastest regional growth

Ovarian Cancer Diagnostics Market Size Worth $2 Billion By 2026

The global ovarian cancer diagnostics market size is expected to reach USD 2 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 6.2%. The growth of the market can be attributed to an increase in the prevalence of ovarian cancer and emergence of novel diagnostic products. As of 2018, ovarian cancer had the highest mortality rate of all gynecologic cancers. It accounted for nearly 14,000 deaths in the U.S. in 2018. No specific symptoms render early diagnosis of the disease increasingly difficult. The exact causative factors remain unknown, creating a key unmet need for further research to obtain clarity on the underlying molecular mechanisms.

Women aged 60 years & above have a higher predisposition to it. As it is often diagnosed in advanced stages, treatment options are limited. Moreover, on the basis of race, incidence rates were higher among Caucasian women than African-American women. The International Federation of Gynecology and Obstetrics (FIGO) system is used for staging ovarian cancer. Staging process helps identify ovarian tumors, calculate their size, and detect invasion & metastasis.

Early detection and diagnosis significantly improve patient survival rates. For instance, in case of epithelial tumors, patients with stage 1 ovarian cancer have a survival rate of nearly 90%, whereas patients with stage 4-the most advanced phase-have a mere 15% survival rate. Technological advancements in PET and MRI as well as in diagnosis of BRCA mutations have positively impacted market growth.

The diagnostic landscape is gradually shifting toward genetic testing and counseling. As the disease bears a high risk of inheritance of gene mutation, guidelines pertaining to ovarian cancer diagnostics recommend all patients to undergo genetic counseling and testing. Earlier, BRCA1/2 was the most prominent test; however, advancements in medical science have now made it possible to test more than 20 genes in each patient.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/ovarian-cancer-diagnostics-market

Further key findings from the report suggest:

Incidence of ovarian cancer worldwide has been declining over the past decades
Although ultrasound imaging is the fist-line of diagnosis, the technique cannot be used for staging the disease
Computerized Tomography (CT) imaging is preferred for staging the disease
CA125 remained the mainstay in blood test biomarkers in 2018
HER2 and BRCA1/2 tests are expected to witness a rapid growth during the forecast period owing to the rising awareness of early diagnosis and genetic tests
The ovarian cancer diagnostics market in Asia Pacific is expected to grow at a high rate during the forecast period.

Predictive Genetic Testing & Consumer/Wellness Genomics Market Worth $8.5 Billion By 2025

The global predictive genetic testing & consumer/wellness genomics market size is expected to reach USD 8.5 billion by 2025, registering a CAGR of 13.9% over the forecast period, according to a new report by Grand View Research, Inc. Factors influencing the market progression include growing awareness about utilization of genetic tests that aid in prediction of gene susceptibility to disease development prior to symptoms. Moreover, rise in sales of these products owing to growing inclination of physicians is driving the market.

Introduction of novel platforms in next-generation sequencing technology aids in enhancing the accuracy of predictive genetic and consumer genomics kits. Market participants are engaged in implementing novel protocols to launch products that require minimal technical assistance and provide optimal customer satisfaction.

Pharmaceutical firms are engaged in several agreement models with genomic vendors for the release of novel therapeutics based on patient’s phenotypic and genotypic information. For instance, in July 2018, GlaxoSmithKline plc purchased 23andMe’s customer data to develop a new drug, thus promoting patient-centered healthcare.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/predictive-genetic-testing-consumer-wellness-genomics-market

Further key findings from the study suggest:

High adoption rate of these products in clinical practice for detection of disease susceptibility resulted in the largest share of this segment in 2018
Growing awareness related to direct to consumer (DTC) genetic tests and entry of new players is attributive to the fastest growth of the consumer genomics segment
Genetic susceptibility tests are of great interest in gynecology and endocrinology-related research and diagnosis, thus allowing it to capture the maximum revenue share. These tests enable the identification of susceptible genes or mutations in adenomyosis, endometriosis, and postmenopausal osteoporosis
Application of predictive genetic and consumer genomics is highest in the detection of breast and ovarian cancer as these tests hold the potential to identify BRCA mutations in patients
Advent of predictive tests for identification of MLH1, MSH2 genes for colorectal cancer diagnosis is expected to fuel market growth in the coming years
Colorectal screening initiatives such as mass screening and population-based screening are expected to boost segment growth
North America dominated the market with the largest revenue share in 2018 owing to the presence of major players and high adoption rate
Asia Pacific is expected to witness substantial growth in the coming years owing to increasing adoption of these products in developing economies
Manufacturers contributing significantly to market growth include Pathway Genomics; ARUP Laboratories; BGI; Illumina, Inc.; 23andMe, Inc.; Color Genomics Inc.; and Myriad Genetics, Inc. Established as well as emerging companies are involved in adopting strategic moves for the launch of novel products.

Preimplantation Genetic Testing Market Worth $107.3 Million By 2024

The global preimplantation genetic testing market is expected to reach USD 107.3 million by 2024, at a CAGR of 6.2% over the forecast period, according to a new report by Grand View Research, Inc. It is primarily driven by a rising awareness among couples to undergo diagnostic and screening tests to minimize genetic diseases and aneuploidy in fetus. The ability of preimplantation genetic testing to detect genetic disorders and rare diseases, such as fibrodysplasia ossificans progressive, is anticipated to propel the growth.

High adoption of In Vitro Fertilization (IVF) technique consequently upsurges the utilization of Preimplantation Genetic Diagnosis (PGD). These techniques are advantageous in a way that they allow the development of a healthy fetus and prevent the risk of selective pregnancy termination. Hence, PGT acts as an addendum to assisted reproductive technology.

A substantial number of patients with infertility and impaired fecundity are recommended to embrace IVF therapy in combination with PGT procedures, which in turn is expected to stimulate the growth. In addition, public and private authorities are promoting reproductive health by undertaking initiatives is also anticipated to drive the Preimplantation Genetic Testing (PGT) (PGS/PGD) market.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/preimplantation-genetic-testing-pgt-market

Further key findings from the report suggest:

Availability of a significant number of services related to early diagnosis of specific gene mutation in embryo marked the dominant position of PGD in 2018
Preimplantation Genetic Screening (PGS) seems to be reasonable intervention to enhance efficiency of selecting chromosomally normal embryo during IVF cycles. It is increasingly being applied for embryo screening due to ever-expanding IVF, which is projected to create lucrative growth opportunities in near future
Advancements in detection of chromosomal anomalies by executing non-invasive prenatal testing results in a maximum share of this segment in 2018
Expanding utilization rate of FISH probe sets and benefits associated with the detection of a single-gene disorder is expected to fuel the growth of X-linked diseases segment
Implementation of PGT in embryo HLA typing for stem cell therapy is expected to impose segment growth. This is further attributed to the advantages pertaining to PGS testing for identification of HLA compatible embryos during stem cell therapy
Europe accounts for largest revenue share in 2018 owing to increased usage of PGD and PGS for the delivery of genetically healthy offspring during IVF procedures
Asia Pacific market is observed to reveal the fastest CAGR due to the rise in medical tourism and the continuous development of IVF and PGD clinics in Asian countries
Key players that have commercialized PGT services include Natera, Inc.; CooperSurgical, Inc.; F. Hoffmann-La Roche AG; Illumina, Inc.; IGENOMIX; and others
Key participants are actively involved in expansion of the distribution network for their products as well as R&D activities for the development of novel PGT services. In October 2018, Illumina Inc. signed an agreement with Vitrolife AB under which Vitrolife act as a distributor supplier of Illumina’s PGT products in EMEA and America.

Cancer Diagnostics Market Worth $249.6 Billion By 2026

The global cancer diagnostics market size is expected to reach USD 249.6 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a 7.0% during the forecast period. Continual introduction of innovative products, coupled with increasing need for early diagnosis of various diseases, is a prime factor driving the market. In addition, rapid growth of the healthcare and diagnostics sector can be attributed to penetration of technologically advanced laboratory systems that have improved oncological screening in yielding accurate outcomes. Rising incidence of cancer is triggering demand for these screening tests and imaging modalities used for monitoring disease progression.

Collaborative and independent initiatives led by governments and companies are striving to raise cognizance about the benefits of early cancer diagnosis. In addition, cancer research organizations, along with public and private entities, are investing heavily on research projects to launch advanced diagnostic tools in the market, which are capable of diagnosing the disease much before the symptoms appear.

Furthermore, giant players are collaborating with governments and other agencies to enhance patient accessibility to these tests and products. For instance, Illumina, Inc. launched a new venture called GRAIL with investors, Jeff Bezos and Bill Gates, with an investment of more than USD 100 million. GRAIL is mainly focused on blood-based oncological screening for timely diagnosis of the most common tumor types through simple laboratory tests.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/cancer-diagnostics-market

Further key findings from the report suggest:

Rapid adoption of technology and escalating need for early diagnosis is augmenting the growth of imaging systems. Thus, the segment is expected to exhibit the fastest CAGR at 8.0% during the forecast period
The breast cancer segment accounted for the largest share based on application due to high incidence rate of breast cancer triggering the need for its early diagnosis
In 2018, North America dominated the global space with the largest revenue share of 42.0%. Focused research efforts in oncology for development of early tumor detection tools, coupled with grants from government healthcare agencies, are contributing to a strong medical ecosystem to fight cancer in this region
Asia Pacific is expected to emerge as the fastest growing region during the forecast period. Favorable regulatory framework and growing patient pool in India, China, and Japan due to support in diagnostic process at comparatively lower prices are some of the factors boosting the market growth in this region
Major players competing in this market include GE Healthcare; Abbott; Hoffmann-La Roche Ltd.; and Siemens Healthcare GmbH. Other prominent players include but are not limited to Becton Dickinson & Company; Illumina, Inc.; Koninklijke Philips N.V.; and Hologic, Inc.

Rare Disease Genetic Testing Market Size Worth $1.8 Billion By 2027

The global rare disease genetic testing market size is expected to reach USD 1.8 billion by 2027 expanding at a CAGR of 10.8% over the forecast period, according to a new report by Grand View Research, Inc. Conventional test methods provide delayed diagnosis. Moreover, patients need to visit physicians to correctly identify a rare condition, leading to an increased healthcare spending. This has spurred the adoption of genetic test methods for accurate and timely identification of rare conditions.

Ongoing scientific advances in this area have created new opportunities for the companies to develop solutions that can impact the management of the rare condition. Collaborations are being undertaken not only across diverse medical and scientific domains but also with various stakeholder groups, such as researchers, patients, and regulators, for new test development, thereby driving the market.

For instance, in October 2018, PerkinElmer Genomics signed an agreement with Sanofi Genzyme to introduce a free genetic testing program called the Lantern Project. The initiative was designed for patients who have or are suspected of having, certain types of lysosomal storage disorders, including Gaucher disease.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/rare-disease-genetic-testing-market

Further key findings from the report suggest:

Neurological disorders accounted for the major revenue share in 2019 owing to availability of a substantial number of test offerings by various companies, such as Invitae and Centogene
Furthermore, the National Institute of Neurological Disorders and Stroke supports research studies for a wide range of diseases, thereby positively impacting the segment growth
Availability and adoption of NGS-based gene panels for cancer, neurologic disease, CVDs, and other rare disease testing has driven the NGS segment
NGS has enabled rapid and cost-effective genetic testing by helping in determining the relevance of de novo and mosaic mutations
It has also helped in detecting the wide phenotypic spectrum of genes, digenic inheritance, and presence of more than one rare condition in the same individual
Thus, a significant decline in the cost of NGS has driven its adoption for molecular testing, contributing to the large share of molecular genetic tests
Laboratories are engaged in conducting a substantial number of genetic tests. This includes labs that are accredited with CLIA for clinical cytogenetics, pathology, and chemistry, among other specialties
Furthermore, regulatory bodies play a major role in the growth of this segment, as they help laboratories conduct effective and safe genetic testing, leading to their dominance as end-user of the market
North America led the global market in 2019 owing to the presence of key research and diagnostic laboratories in U.S.